A change has occurred in the shareholding status of the largest shareholder side of Kukje Pharmaceutical. The reported reasons include share gifting and receipt of gifted shares, as well as the addition of an executive. Although the number of shares held increased, the ownership ratio remained unchanged from before. Following the disclosure, Kukje Pharmaceutical's stock price fell 195 won from the previous trading day to 4,235 won, a decline of approximately 4.40%.

◆ Largest Shareholder Nam Young-woo Cites the 6th of This Month as Reporting Obligation Date

According to the report on major shareholding status submitted by Kukje Pharmaceutical, the reporter Nam Young-woo reported the change in shareholding status with the 6th of this month as the date on which the reporting obligation arose. This report was filed under Article 147 of the Financial Investment Services and Capital Markets Act, and was prepared in the standard format for purposes of influencing management control. The report states that Nam Young-woo's relationship with the issuing company is that of largest shareholder.

◆ Holdings Increase by 887 Shares to 8,031,092... Ownership Ratio Unchanged at 37.95%

The number of shares held, which was 8,030,205 in the previous report, increased to 8,031,092 in this report. The increase amounts to 887 shares. However, the ownership ratio was identical in both the previous and current reports at 37.95%. While the number of shares changed, the overall ownership ratio remained the same.

The same change was confirmed in voting rights. The number of voting rights listed in the previous report was 8,030,205, which increased to 8,031,092 in this report. The voting rights ownership ratio was also maintained at 37.95%.

◆ No Change in Shares Under Major Contracts

There was no change in the number and ratio of shares under major contracts. Both the previous and current reports listed the number of shares under major contracts at 3,957,991, with the ratio identical at 18.71%. The number of voting rights under major contracts also remained unchanged at 3,957,991, with the ratio maintained at 18.71%.

◆ Reasons for Change Cited as 'Share Gift and Receipt, Executive Addition'... Individual Details Not Disclosed

The reasons for the change stated in this report are the gifting and receipt of shares and the addition of an executive. However, the summary information in the provided report does not include individual changes in quantities from the share gifts or specific details about the added executive.

Therefore, the confirmed facts are: ▲ the number of shares held increased by 887 shares compared to the previous report, ▲ the overall ownership ratio was maintained at 37.95%, and ▲ there was no change in the number and ratio of shares under major contracts. Ultimately, this disclosure indicates that while some changes occurred in the shareholding status of the largest shareholder side, the overall ownership ratio and the ratio of shares under major contracts remain at previous levels.

[This article was written based on the report on major shareholding status submitted by Kukje Pharmaceutical and the provided stock price data. Individual gift amounts or shareholding changes not confirmed in the provided materials were not included. This article is not a recommendation to invest in any particular stock, and stock prices may fluctuate depending on market conditions. Investment decisions and the responsibility arising from them rest with the investor. This article was written with the help of AI.]